 |
|
|
| |
Ledipasvir/Sofosbuvir (LDV/SOF) for 12 or 24 Weeks Is Safe and Effective in Kidney Transplant Recipients With Chronic Genotype 1 or 4 HCV Infection
|
| |
| |
Reported by Jules Levin
EASL 2016 April 14-17 Barcelona
Massimo Colombo1, Alessio Aghemo1, Hong Liu2, Hadas Dvory-Sobol2, Robert H. Hyland2, Chohee Yun2, Diana M.
Brainard2, John G. McHutchison2, Marc Bourlière3, Markus Peck-Radosavljevic4, Michael Manns5, Stanislas Pol6
1Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy;
2Gilead Sciences Inc., Foster City, California, USA; 3Hôpital Saint Joseph, Marseilles, France; 4Medical University of Vienna, Vienna, Austria; 5Hannover Medical School, Hannover, Germany; 6Hôpital Cochin, Paris, France
|
| |
|
|
|
|
|
